All Products
Men Care
Women Care
Sexual Wellness
Herbal & Homeopathy
Baby & Mom Care
Personal Care
Trizidim IV/IM 250 mg/vial
Injection
Pack Size :
1 injection x 1 Packet
Generics :
Ceftazidime
Manufacturer :
Acme Laboratories Ltd.
Best Price *
TK
70.47
Refrigerated
* Delivery will be done in Dhaka city only.
Alternative Product
More Information About - Trizidim IV/IM 250 mg/vial
Description
Generic Name
CeftazidimePrecaution
History of penicillin allergy; severe renal impairment; pregnancy, lactation. Lactation: Drug excreted in breast milk; use with cautionIndication
Pneumonia, Cystic fibrosis, Bacterial septicemia, Meningitis, Peritonitis, Skin and Skin-Structure Infections, Endometritis, Pelvic cellulitis, Respiratory tract infections, Urinary tract infections, Febrile neutropenia, Melioidosis, Bone and Joint Infections,G ynecologic Infections, Biliary tract infections, EndophthalmitisContra Indication
Hypersensitivity to cephalosporins.Dose
N/ASide Effect
1-10% Transient increases in transaminases (3-9%),Eosinophilia (<7%),Diarrhea (<2%),Immune hypersensitivity reaction (2%),Phlebitis (<2%),Rash (maculopapular or erythematous) (2%),Thrombocytosis (2%),Injection site pain (1%) <1% Abdominal pain,Agranulocytosis,Angioedema,Asterixis,Coma,Dizziness,Encephalopathy,Fever,Hallucinations,Increased serum concentrations of bilirubin,Leukopenia,Lymphocytosis,Metallic taste,Myoclonia,Nausea or vomiting,Neuromuscular excitability,Neutropenia,Paresthesia,Photosensitivity,Pruritus,Seizures,Thrombocytopenia,Transient increases in blood urea nitrogen (BUN) or serum creatinine,Urticaria Potentially Fatal: Anaphylactic reactions, nephrotoxicity, pseudomembranous colitis.Pregnancy Category
Name : B
Description
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.Mode of Action
Ceftazidime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.Interaction
May increase nephrotoxicity of aminoglycosides. May diminish therapeutic effect of BCG, typhoid vaccine, Na picosulfate. May increase anticoagulant effect of vit K antagonists (e.g. warfarin). May increase serum level w/ probenecid.Pregnancy Category Note
Pregnancy category: B Lactation: Drug excreted in breast milk; use with cautionAdult Dose
Bone & Joint Infections 2 g IV q12hr Gynecologic & Intra-abdominal Infections, Meningitis, Complicated Pneumonia, Life-Threatening Infections 2 g IV q8hr Pulmonary Infections Infections caused by Pseudomonas spp in patients with cystic fibrosis who have healthy renal function 30-50 mg/kg IV q8hr; not to exceed 6 g/day Uncomplicated Pneumonia 0.5-1 g IV q8hr Mild Skin/Skin Structure Infections 0.5-1 g IV or IM q8hr Urinary Tract Infections Complicated: 500 mg IV or IM q8-12hr Uncomplicated: 250 mg IV or IM q12hr Elderly: >80 yr Max: 3 g daily.Child Dose
Child: IV, IM 90?150 mg/kg/day q8h IV 200?300 mg/kg/day for serious Pseudomonas infection (max 8?12 g/day) q8hRenal Dose
Renal impairment: Loading dose: 1 g; maintenance doses based on CrCl. May need to increase doses by 50% in severe infections. Peritoneal dialysis: Loading dose is followed by 500 mg every 24 hr; may add ceftazidime to the dialysis fluid (usually 125-250 mg for 2 litres of dialysis fluid). Haemodialysis: Admin loading dose then 0.5-1 g after each dialysis period. CrCl (ml/min) 31-50 1 g every 12 hr. 16-30 1 g every 24 hr. 6-15 500 mg every 24 hr. <5 500 mg every 48 hr.Administration
IV/IM Administration IV Direct injection: Inject over 3-5 minutes directly into vein or through tubing of running compatible infusion solution Infusion: Infuse intermittently over 15-30 minutes IM Inject deeplyDisclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.
Others Product
In Stock
Prescribed
In Stock
Prescribed
In Stock
In Stock
